Bogart David Robert reported option exercise involving 750,000 derivative units of Conexeu Sciences Inc. at $0.00 for $0 on Sep 25, 2026

Option exercise
Form 4 code M. Exercise or conversion of a derivative security exempt under Rule 16b-3.
Chief Commercial Officer
Chief Commercial Officer
Filed Sep 28, 2026

Facts from the filing

Form 4 · Derivative, table II
Disclosed value
$0Shares × reported price
Shares traded
750,000Performance Warrants
Price per share
$0.00Reported price. Read footnotes for ranges.
% of reported position traded
UnavailableThis security and ownership context
Holdings after
250,000Direct
Trade date
Sep 25, 2026Option exercise
Filed
Sep 28, 2026, 5:38 PM ET3-day reporting delay
Accession
0001062993-26-005090Code M · Transaction 230567
How reported position traded is calculated

Not calculated for derivative securities.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Other trades in this filing

Trade dateActivitySharesPriceValueDetails
Sep 25, 2026Option exercise750,000$0.00$750Trade 230566
2 transaction rows in this filing. Joint filers share the same rows.

CNXU price since this filing

Daily closing prices, with the filing date and available return windows. Return methodology
CNXU · Daily closing priceDaily price data is pending. The chart appears when valid daily closes are available.
Filing dateReturn windows appear as prices become available.
Pre-filing1mo ago1w ago +32%1d ago +5%
Returns since7d −17%30d −24%90d180d1y

Footnotes in full

F1: The transaction is also exempt from Section 16(b) of the Securities Exchange Act of 1934, as amended (the "Act") pursuant to Rule 16b-6(b) promulgated under the Act. F2: Held by 0865546 B.C. Ltd., over which the Reporting Person has sole voting and dispositive power. F3: The Performance Warrants were granted on June 5, 2025 and have an exercise price of $0.001 and a term of 5 years. The Performance Warrants were granted for services rendered to the issuer and no price was paid for the Performance Warrants. 750,000 Performance Warrants have vested. The remaining 250,000 Performance Warrants will vest and be exercisable upon the Issuer submitting a 510(k) application to the United States Food and Drug Administration.